Edwards Lifesciences is expected to report consensus revenue of $1.70 billion and EPS of $0.73 for the second quarter, with the stock currently trading at $85.00 against an average analyst price target of $97.15. Investors are primarily focused on growth within the Transcatheter Aortic Valve Replacement (TAVR) segment, which serves as the company's core revenue driver.
Analysts are looking for continued momentum in the SAPIEN valve platform following a strong first-quarter performance and a subsequent raise in full-year guidance. Key developments to watch include procedural volume trends and potential market share gains in Europe following a competitor's recent exit from the market.